{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:45:32Z","timestamp":1790376332943,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research: Neuroimaging"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.pscychresns.2020.111080","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T20:38:56Z","timestamp":1585946336000},"page":"111080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Glutamate metabolites in treatment resistant schizophrenia: A meta-analysis and systematic review of 1H-MRS studies"],"prefix":"10.1016","volume":"300","author":[{"given":"Vijay","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayanth","family":"Manchegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpitha","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naren P","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pscychresns.2020.111080_bib0001","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1523\/JNEUROSCI.18-14-05545.1998","article-title":"Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine","volume":"18","author":"Adams","year":"1998","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0002","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamapsychiatry.2017.2663","article-title":"Heterogeneity and homogeneity of regional brain structure in schizophrenia: a meta-analysis","volume":"74","author":"Brugger","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0003","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.schres.2013.02.026","article-title":"Factor structure of the matrics consensus cognitive battery (MCCB) in schizophrenia","volume":"146","author":"Burton","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0004","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.biopsych.2019.02.003","article-title":"Glutamatergic system and neuroimaging studies of treatment-resistant schizophrenia","volume":"85","author":"Chouinard","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.biopsych.2017.09.028","article-title":"Prefrontal and striatal gamma-aminobutyric acid levels and the effect of antipsychotic treatment in first-episode psychosis patients","volume":"83","author":"de la Fuente-Sandoval","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0006","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function","volume":"75","author":"Demjaha","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0007","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0008","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41380-018-0082-9","article-title":"Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE)","volume":"23","author":"Egerton","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0009","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1038\/npp.2012.113","article-title":"Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia","volume":"37","author":"Egerton","year":"2012","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.psc.2007.04.001","article-title":"Treatment-resistant schizophrenia","volume":"30","author":"Elkis","year":"2007","journal-title":"Psychiatr. Clin. North Am"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0011","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.psc.2016.01.006","article-title":"Treatment-resistant schizophrenia","volume":"39","author":"Elkis","year":"2016","journal-title":"Psychiatr. Clin. North Am"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0012","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12888-016-1177-y","article-title":"Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review","volume":"17","author":"Gillespie","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0013","article-title":"Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia","volume":"18","author":"Goldstein","year":"2015","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0014","first-page":"119","article-title":"Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia","volume":"8","author":"Goto","year":"2012","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0015","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies","volume":"69","author":"Howes","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pnpbp.2015.08.010","article-title":"Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones","volume":"65","author":"Iasevoli","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0017","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.biopsych.2018.09.009","article-title":"Glutamatergic neurometabolite levels in patients with ultra-treatment-resistant schizophrenia: a cross-sectional 3T proton magnetic resonance spectroscopy study","volume":"85","author":"Iwata","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0018","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.mp.4001552","article-title":"Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action","volume":"10","author":"Javitt","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0019","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0020","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/0706743718772522","article-title":"Delayed initiation of clozapine continues to be a substantial clinical concern","volume":"63","author":"John","year":"2018","journal-title":"Can. J. Psychiatry Rev. Can. Psychiatr."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0021","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/archgenpsychiatry.2011.1519","article-title":"Elevated prefrontal cortex \u03b3-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy","volume":"69","author":"Kegeles","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0022","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","article-title":"The social and economic burden of treatment-resistant schizophrenia: a systematic literature review","volume":"29","author":"Kennedy","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0023","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/npp.2016.258","article-title":"Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: an [18F]DOPA pet study","volume":"42","author":"Kim","year":"2017","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0024","unstructured":"Lehman, A.F., Lieberman, J.A., Dixon, L.B., McGlashan, T.H., Miller, A.L., Perkins, D.O., Kreyenbuhl, J., American psychiatric association, steering committee on practice guidelines, 2004. Practice guideline for the treatment of patients with schizophrenia, 2nd edition. Am. J. Psychiatry 161, 1\u201356."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0025","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0026","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0027","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/schbul\/sbv151","article-title":"Treatment-Resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive","volume":"42","author":"Mouchlianitis","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0028","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/2041-210X.12309","article-title":"Meta-analysis of variation: ecological and evolutionary applications and beyond","volume":"6","author":"Nakagawa","year":"2015","journal-title":"Methods Ecol. Evol."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0029","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","article-title":"Glutamate receptor dysfunction and schizophrenia","volume":"52","author":"Olney","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia","volume":"33","author":"Olney","year":"1999","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0031","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/mp.2013.136","article-title":"Imaging glutamate in schizophrenia: review of findings and implications for drug discovery","volume":"19","author":"Poels","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0032","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.biopsych.2005.08.029","article-title":"A pharmacological model for psychosis based on N-methyl-d-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities","volume":"59","author":"Rujescu","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0033","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0034","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0035","first-page":"114","article-title":"Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex","volume":"52","author":"Schwieler","year":"2004","journal-title":"Synap. N. Y. N"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0036","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatry Rev. Can. Psychiatr."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0037","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/j.1476-5381.2011.01638.x","article-title":"Clozapine, but not haloperidol, enhances glial d-serine and l-glutamate release in rat frontal cortex and primary cultured astrocytes","volume":"165","author":"Tanahashi","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0038","series-title":"R: A Language and Environment for Statistical Computing","year":"2020"},{"key":"10.1016\/j.pscychresns.2020.111080_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.pscychresns.2020.111080_bib0040","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1001\/jamapsychiatry.2018.2467","article-title":"Mapping the heterogeneous phenotype of schizophrenia and bipolar disorder using normative models","volume":"75","author":"Wolfers","year":"2018","journal-title":"JAMA Psychiatry"}],"container-title":["Psychiatry Research: Neuroimaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925492720300524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925492720300524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:34:16Z","timestamp":1760420056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925492720300524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":40,"alternative-id":["S0925492720300524"],"URL":"https:\/\/doi.org\/10.1016\/j.pscychresns.2020.111080","relation":{},"ISSN":["0925-4927"],"issn-type":[{"value":"0925-4927","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glutamate metabolites in treatment resistant schizophrenia: A meta-analysis and systematic review of 1H-MRS studies","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research: Neuroimaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pscychresns.2020.111080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111080"}}